Pitcairn Co. Sells 20,260 Shares of Bristol Myers Squibb Company $BMY

Key Points

• Pitcairn Co. cut its stake in Bristol Myers Squibb by 67%, selling 20,260 shares and leaving 9,984 shares valued at about $450,000.
• BMS missed Q4 consensus with $1.26 EPS (vs. ~$1.65) although revenue was roughly in line; the company set FY2026 guidance of 6.05–6.35 EPS and declared a quarterly dividend of $0.63 (4.2% yield).
• Positive product catalysts include an FDA label expansion for Sotyktu in psoriatic arthritis and Reblozyl surpassing $2.3B in annualized sales, which could help offset pressures from legacy drugs.

Pitcairn Co. trimmed its holdings in Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 67.0% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 9,984 shares of the biopharmaceutical company's stock after selling 20,260 shares during the period. Pitcairn Co.'s holdings in Bristol Myers Squibb were worth $450,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also made changes to their positions in the company. Darwin Wealth Management LLC bought a new stake in shares of Bristol Myers Squibb during the 2nd quarter valued at $25,000. Harbor Capital Advisors Inc. grew its holdings in shares of Bristol Myers Squibb by 107.2% during the 3rd quarter. Harbor Capital Advisors Inc. now owns 605 shares of the biopharmaceutical company's stock worth $27,000 after purchasing an additional 313 shares in the last quarter. Total Investment Management Inc. bought a new position in shares of Bristol Myers Squibb in the second quarter worth $38,000. Twin Peaks Wealth Advisors LLC acquired a new position in Bristol Myers Squibb in the second quarter valued at about $40,000. Finally, Bank of Jackson Hole Trust raised its stake in Bristol Myers Squibb by 352.2% in the third quarter. Bank of Jackson Hole Trust now owns 1,040 shares of the biopharmaceutical company's stock valued at $47,000 after purchasing an additional 810 shares in the last quarter. 76.41% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on BMY shares. The Goldman Sachs Group reiterated a "neutral" rating and set a $57.00 price objective (up from $51.00) on shares of Bristol Myers Squibb in a research note on Tuesday, December 2nd. BMO Capital Markets restated a "market perform" rating on shares of Bristol Myers Squibb in a research report on Monday, November 17th. Guggenheim reaffirmed a "buy" rating and set a $72.00 price target (up from $62.00) on shares of Bristol Myers Squibb in a report on Friday, February 6th. Morgan Stanley reissued an "underweight" rating and issued a $40.00 price objective on shares of Bristol Myers Squibb in a research note on Friday, February 6th. Finally, Cantor Fitzgerald restated a "neutral" rating on shares of Bristol Myers Squibb in a research report on Monday, November 24th. Nine investment analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Hold" and a consensus price target of $61.00.

Bristol Myers Squibb News Roundup

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: U.S. FDA approved Sotyktu (deucravacitinib) for adults with active psoriatic arthritis — a label expansion that can broaden Sotyktu’s market opportunity and revenue runway. U.S. FDA Approves Bristol Myers Squibb's Sotyktu® (deucravacitinib) for the Treatment of Adults with Active Psoriatic Arthritis
• Positive Sentiment: BMY declared a quarterly dividend of $0.63/share (ex-dividend April 2), maintaining a high-yield payout that supports income-focused investors and can underpin the stock’s valuation. Dividend Announcement
• Positive Sentiment: Reblozyl showed positive Phase 2 results in alpha-thalassemia and has exceeded $2.3B in annualized sales — evidence Reblozyl is becoming a material growth driver as older drugs decline. Reblozyl Phase 2 Success Shapes Bristol Myers Squibb Valuation Story
• Neutral Sentiment: Bristol-Myers Squibb is tracking the real-world impact of KarXT in schizophrenia — useful clinical/market data but longer-term and unlikely to move near-term earnings. Bristol-Myers Squibb Tracks Real-World Impact of KarXT in Schizophrenia
• Negative Sentiment: Q4 results showed revenue roughly in line but EPS missed consensus (reported $1.26 vs. ~$1.65 expected), which prompted investor selling and weighed on the stock. Earnings and Market Reaction
• Negative Sentiment: Recent articles highlight a larger-than-market intraday decline and analyst focus on legacy-product pressures — shorter-term sentiment and volatility remain a risk until new product growth scales. Bristol Myers Squibb (BMY) Registers a Bigger Fall Than the Market

Bristol Myers Squibb Stock Performance

Shares of BMY stock opened at $60.21 on Monday. The firm has a market capitalization of $122.62 billion, a price-to-earnings ratio of 17.45, a PEG ratio of 0.17 and a beta of 0.26. The company has a current ratio of 1.26, a quick ratio of 1.14 and a debt-to-equity ratio of 2.32. The business's 50-day moving average price is $57.66 and its 200-day moving average price is $51.03. Bristol Myers Squibb Company has a 12 month low of $42.52 and a 12 month high of $63.33.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last released its quarterly earnings data on Thursday, February 5th. The biopharmaceutical company reported $1.26 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.65 by ($0.39). The firm had revenue of $12.50 billion during the quarter, compared to analyst estimates of $12.24 billion. Bristol Myers Squibb had a net margin of 14.64% and a return on equity of 69.65%. The business's quarterly revenue was up 1.3% compared to the same quarter last year. During the same period in the prior year, the company earned $1.67 EPS. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. Equities research analysts forecast that Bristol Myers Squibb Company will post 6.74 EPS for the current year.

Bristol Myers Squibb Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, May 1st. Stockholders of record on Thursday, April 2nd will be paid a dividend of $0.63 per share. The ex-dividend date of this dividend is Thursday, April 2nd. This represents a $2.52 annualized dividend and a dividend yield of 4.2%. Bristol Myers Squibb's dividend payout ratio (DPR) is presently 73.04%.

Bristol Myers Squibb Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company's core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS's marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.